


Agilent Technologies

Q4 Fiscal Year 2013 Results



November 14, 2013



Safe Harbor




This presentation contains forward-looking statements (including, without limitation, information and future guidance on our goals, priorities, revenues, demand, growth opportunities, customer service and innovation plans, new product introductions, financial condition, earnings, the continued strengths and expected growth of the markets we sell into, operations, operating earnings, and tax rates) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended July 31, 2013.

The company assumes no obligation to update the information in these presentations. These presentations and the Q&A that follows include non-GAAP numbers. A presentation of the most directly comparable GAAP numbers and the reconciliations between the non-GAAP and GAAP numbers can be found at <http://www.investor.agilent.com> under "Financial Results" and accompany this slide set.

Q4'13 Financial Highlights

- **Orders:** \$1.83B, +4% y/y (+6% core*)
- **Revenues**:** \$1.72B, -3% y/y (-1% core*)
- **Operating Margin**:** 20.4% of revenue, -130 basis points y/y
- **Operating Cash Flow:** \$377M, -\$108M y/y




*Core revenue growth excludes the impact from M&A and FX. ** Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided.


Q4'13 Revenue Distribution

Q4'13 Revenue: \$1.72B

Q4'13 Revenue by Segment






Q4'13 Revenue by Region



Q4'13 Revenue Distribution by Geography

- Q4'13 Y/Y revenue** growth:
 - Americas -9% (-9% core*)
 - Europe +7% (+4% core*)
 - Japan -18% (flat core*)
 - Asia Pacific ex-Japan +3% (+3% core*)




*Core revenue growth excludes the impact from M&A and FX. ** Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided.

Q4'13 LDA Markets Highlights


Life Sciences, Diagnostics, and Applied Markets

- **Orders:** \$1.1B, +9% y/y (+10% core*)
- **Revenues:** \$1.0B, +6% y/y (+8% core*)
- **Operating Margin:** 21.4% of revenue, +100 basis points y/y


LDA Net Revenue



Q4'13 LDA Revenue by Region



LDA Income from Operations




*Core revenue growth excludes the impact from M&A and FX.


Q4'13 EMG Highlights

- **Orders:** \$742M, -2% y/y (+1% core*)
- **Revenues:** \$705M, -14% y/y (-12% core*)
- **Operating Margin:** 19% of revenue, -420 basis points y/y


EMG Net Revenue



Q4'13 EMG Revenue by Region






EMG Income from Operations



*Core revenue growth excludes the impact from M&A and FX.

Q4'13 LDG Highlights




- **Orders:** \$642M, +12% y/y (+13% core*)
- **Revenues:** \$601M, +8% y/y (+9% core*)
- **Operating Margin:** 19.2% of revenue, +180 basis points y/y



*Core revenue growth excludes the impact from M&A and FX.

Q4'13 CAG Highlights


- **Orders:** \$445M, +6% y/y (+7% core*)
- **Revenues:** \$412M, +4% y/y (+6% core*)
- **Operating Margin:** 24.7% of revenue, +10 basis points y/y



*Core revenue growth excludes the impact from M&A and FX.

Q4'13 Revenue Distribution by End Market

Q4'13 Revenue: \$1.72B




Agilent End Market Performance – Q4'13

Mixed results:

Up: Pharma & Biotech, Academia & Government, Diagnostics & Clinical, Food, Chemical & Energy

Down: Communications, Aerospace & Defense, Industrial/ Computers/Semi

Flat: Environmental & Forensics



End Markets	% of Agilent Revenue ⁽¹⁾	Market Size ⁽²⁾ \$54B	Agilent Results Q4'13 vs. Q4'12
Communications	14%	\$4B	Down 19% on continued softness in handset manufacturing test
Aerospace & Defense	10%	\$3B	Down 11% with lower demand in the U.S. and Asia partially offset by strength in Europe
Industrial, Computers, Semiconductor	18%	\$6B	Down 10% on continued weakness in semi manufacturing and industrial markets
Pharma & Biotech	15%	\$11B	Up 10% on technology upgrades and offshoring to emerging markets
Academia & Government	7%	\$10B	Up 4% on easier compare due to effects of sequestration
Diagnostics & Clinical	7%	\$7B	Up 16% on strength in Dako and record volumes in genomics
Food	6%	\$4B	Up 7% on strength in emerging markets
Environmental & Forensics	9%	\$5B	Flat on weak government spending in Environmental, offset by growth in Forensics
Chemical & Energy	14%	\$4B	Up 5% on strength in emerging markets

(1) Percentage of Agilent revenue based on Q1'13-Q4'13

(2) Market size and growth per Company estimates

Q1'14 and FY 2014 Guidance

	Q1'14	FY14
Revenue	\$1.68B - \$1.70B	\$6.95B – 7.15B
Revenue Growth (mid-point)	1%	4%
Core Revenue Growth* (mid-point)	2%	4%
EPS	\$0.65 - \$0.67	\$3.03 - \$3.33
EPS Growth (mid-point)	5%	10%

Presented on a non-GAAP basis; guidance as of November 14th, 2013

*Core revenue growth excludes the impact from M&A and FX.